Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients

Rhea-AI Summary

Guardant Health (Nasdaq: GH) announced new data from its blood tests to be presented at the 2022 ESMO Congress (September 9-13, Paris). It includes findings on liquid biopsy tests to identify biomarkers, predict therapy response, and detect resistance mechanisms in late-stage cancers. Highlights involve oral and poster presentations showcasing significant findings like genomic resistance mechanisms and clinical potential of ctDNA for monitoring treatments. These advancements aim to foster better understanding and outcomes in cancer therapy.

Positive

• Presentation of new data at ESMO emphasizes the utility of blood tests in cancer treatment.
• Findings could lead to advancements in understanding therapy resistance mechanisms.
• Potential to improve patient outcomes through comprehensive genomic profiling.

Negative

• None.

Presentations to highlight role of liquid biopsy tests and real-world data to identify biomarkers, predict patient response to therapy, and detect resistance mechanisms in late-stage cancers

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 European Society for Medical Oncology (ESMO) Congress, September 9-13 in Paris, France. Among the seven abstracts are an oral presentation and posters highlighting the use of Guardant Health’s blood tests and real-world evidence dataset to advance cancer therapy trials, predict and monitor patient response to therapy, and identify genomic mechanisms of acquired resistance to cancer therapy.

“We look forward to sharing new data at ESMO demonstrating the utility of our blood tests to increase the understanding of potential new biomarker targets and the mechanisms of therapy resistance in patients with cancer,” said Helmy Eltoukhy, Guardant Health co-CEO. “The data from retrospective and real-world analyses show how comprehensive genomic profiling tests provide critical insights at every step of a patient’s treatment journey, and ultimately contribute to the development of more effective therapies and improved patient outcomes.”

Full List of Guardant Health Presentations

GuardantOMNI

• Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study (Oral Presentation 316O)
• Interim biomarker analysis of a phase 1b/2 study of anti-TIGIT etigilimab (MPH313) and nivolumab in subjects with select locally advanced or metastatic solid tumors (ACTIVATE) (Presentation 111P)
• Clinical potential of circulating tumor DNA (ctDNA)–based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to first-line (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC) (Presentation 1092P)
• Early decreases in KRAS mutant allele frequency (MAF) predicts clinical benefit to the PLK1 inhibitor onvansertib in combination with FOLFIRI/bev in 2L treatment of metastatic colorectal carcinoma (mCRC) (Presentation 397P)
• The PLK1 inhibitor onvansertib overcomes irinotecan resistance in RAS-mutated (mRAS) metastatic colorectal cancer (mCRC) in vivo and in patients (pts) (Presentation 366P)

Guardant360

• Resistance mechanisms to lorlatinib or crizotinib in treatment-naive patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) (Presentation 1008P)

GuardantINFORM

• Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations (Presentation 1407P)

The full abstracts are available on the official ESMO 2022 website.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield^TM test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005434/en/

Investor Contact:

Alex Kleban

investors@guardanthealth.com

+1 657-254-5417

Media Contact:

Michele Rest

press@guardanthealth.com

+1 215-910-2138

Source: Guardant Health, Inc.

FAQ

What new data did Guardant Health present at ESMO 2022?

Guardant Health presented data on biomarkers, therapy response prediction, and resistance mechanisms in cancer, derived from its blood tests.

How can Guardant Health's tests impact cancer treatment?

The tests may increase understanding of therapy resistance and inform better treatment protocols, potentially improving patient outcomes.

When and where was the ESMO Congress held?

The ESMO Congress took place from September 9 to 13, 2022, in Paris, France.

What is the significance of the findings from Guardant Health's presentations?

The findings are significant as they may offer insights for developing more effective cancer therapies and improving patient management.